Jens Radzimanowski is Director of Antibody Therapeutics Lead Identification at Boehringer Ingelheim Animal Health in Saint‑Priest, France. He leads early discovery teams across hit discovery, lead identification, and platform innovation to advance next‑generation antibody therapeutics for animal health.

Jens holds a PhD in Structural Biology from the University of Heidelberg (Germany). Earlier, as a scientist and deputy lab manager at the European Synchrotron Radiation Facility, he investigated DNA repair mechanisms and supported public and industrial beamline users. He then joined the French biotech company Adocia, first in the formulation department—leading programs from research to Phase III and later in biochemistry, driving mechanism‑of‑action studies, bioanalysis and bioassay development, and coordinating preclinical and clinical activities. He joined Boehringer Ingelheim in 2022.